Corcept Therapeutics (CORT) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenue reached $163.8 million, up 39% year-over-year, with net income at $35.5 million, driven by higher sales volumes, a price increase, and record Korlym prescribers and patients.

• 2024 revenue guidance was raised to $640–$670 million, reflecting commercial strength and growth in the endocrinology division.

• Cash and investments totaled $492.5 million as of June 30, 2024, supporting ongoing R&D and commercial expansion.

• The company launched an authorized generic version of Korlym in June 2024 and continues to advance pivotal trials for relacorilant and dazucorilant.

• Significant clinical milestones achieved, including record new Korlym prescribers, positive GRACE trial results, and major progress in clinical development programs.

Financial highlights

• Q2 2024 product revenue: $163.8 million, up from $117.7 million in Q2 2023.

• Net income for Q2: $35.5 million, up from $27.5 million in Q2 2023.

• Diluted EPS for Q2 2024: $0.32, up from $0.25 in Q2 2023.

• Operating expenses increased to $128.2 million, reflecting higher R&D and SG&A costs.

• Gross margin remained above 98% for Q2 2024.

Outlook and guidance

• 2024 revenue guidance increased to $640–$670 million, reflecting confidence in continued growth.

• Expectation of further patient growth as awareness and screening for hypercortisolism expand.

• Anticipated data from GRADIENT, CATALYST, ROSELLA, and DAZALS studies by year-end.

• NDA submission for relacorilant in Cushing's syndrome expected in Q4 2024.

• Management anticipates funding operations and planned R&D activities for at least the next 12 months without needing to raise additional funds.